Brief: Ryvu Therapeutics Concludes EUR 3.9 Mln Deal For Phase II Clinical Trial Of RVU120

Ryvu Therapeutics SA

02/03/2023 13:40

March 2 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * CONCLUDES AGREEMENT FOR OPERATIONAL EXECUTION OF PHASE II
OF
PHASE I/II CLINICAL TRIAL OF RVU120 IN PATIENTS WITH
RELAPSED/REFRACTORY SOLID TUMORS
    * DEAL WITH LABCORP DRUG DEVELOPMENT
    * ESTIMATED DEAL VALUE AT EUR 3.9 MILLION

Source text for Eikon:  ID:nEM7fCQGra 
Further company coverage:  RVU.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))